- Home
- ATXI vs TOVX Comparison
ATXI vs TOVX Comparison
Compare ATXI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXI
- TOVX
- Stock Information
- Founded
- ATXI 2015
- TOVX 2001
- Country
- ATXI United States
- TOVX United States
- Employees
- ATXI N/A
- TOVX N/A
- Industry
- ATXI Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ATXI Health Care
- TOVX Health Care
- Exchange
- ATXI Nasdaq
- TOVX Nasdaq
- Market Cap
- ATXI 3.0M
- TOVX 3.5M
- IPO Year
- ATXI 2017
- TOVX 2006
- Fundamental
- Price
- ATXI $1.84
- TOVX $1.18
- Analyst Decision
- ATXI
- TOVX Strong Buy
- Analyst Count
- ATXI 0
- TOVX 1
- Target Price
- ATXI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- ATXI 23.5K
- TOVX 97.3K
- Earning Date
- ATXI 11-14-2024
- TOVX 11-12-2024
- Dividend Yield
- ATXI N/A
- TOVX N/A
- EPS Growth
- ATXI N/A
- TOVX N/A
- EPS
- ATXI N/A
- TOVX N/A
- Revenue
- ATXI N/A
- TOVX N/A
- Revenue This Year
- ATXI N/A
- TOVX N/A
- Revenue Next Year
- ATXI N/A
- TOVX N/A
- P/E Ratio
- ATXI N/A
- TOVX N/A
- Revenue Growth
- ATXI N/A
- TOVX N/A
- 52 Week Low
- ATXI $1.60
- TOVX $1.14
- 52 Week High
- ATXI $26.48
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- ATXI 44.82
- TOVX 38.15
- Support Level
- ATXI $1.80
- TOVX $1.23
- Resistance Level
- ATXI $1.88
- TOVX $1.34
- Average True Range (ATR)
- ATXI 0.13
- TOVX 0.08
- MACD
- ATXI -0.01
- TOVX 0.01
- Stochastic Oscillator
- ATXI 40.70
- TOVX 12.50
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.